Biomarker

Biomarker blood test shows cancer recurrence months before CT scans

By | In The Press | No Comments

Prospective clinical trial demonstrates that testing for CTCs reveals lung cancer recurrence an average of six months earlier than conventional scans.

Results from a prospective clinical trial showed that a blood test looking at specific biomarkers was able to detect recurrences of lung cancer an average of six months before conventional imaging methods found evidence of recurrence. In the largest prospective clinical trial to date of circulating tumor cells (CTC) as biomarkers for locally advanced lung cancer, the findings indicate that blood tests potentially can be used in conjunction with CT and PET/CT scans to guide personalized treatment planning for patients with non-small cell lung cancer (NSCLC). The study will be presented today at the 2017 Multidisciplinary Thoracic Cancers Symposium.

Read More

Photography is by Michael Moran for Dezeen.com

Pennovation Center – 21st-century idea factory!

By | In The Press | No Comments

The Website Dezeen just published a new article about the University of Pennsylvania’s Pennovation Center, which we are proud to say is Liquid Biotech USA’s new home.

“The Pennovation Center has already attracted tenants such as Hershey Foods, the largest chocolate manufacturer in North America, and Liquid Biotech, which develops cancer- and gene-related technologies.”

Read the full article here:

Hollwich Kushner creates University of Pennsylvania incubator space with spiky glass facade

Collaboration with the University of Pennsylvania and Funding of Sponsored Research Agreement

By | In The Press | No Comments

Liquid Biotech USA, Inc. Announces Collaboration with the University of Pennsylvania and Funding of Sponsored Research Agreement

PHILADELPHIA, June 27, 2016 /PRNewswire/ — Liquid Biotech USA, Inc. (“Liquid”) today announced the funding of a Sponsored Research Agreement with The University of Pennsylvania (“PENN”) to study circulating tumor cells (CTCs) from cancer patients. The funding will be used to assess how changes in CTC levels correlate with clinical outcomes in cancer patients undergoing a variety of anti-cancer therapies. These data will then be employed to support the design of a therapeutic, decision-making study using CTC enumeration and genetic profiling as personalized real-time guidance. The ultimate goal of these clinical studies is to utilize CTC-derived information to guide anti-cancer therapy and surveillance via Liquid’s precision medicine platform. Read More

Liquid Biotech USA Inc. and MolecularMatch Partner to Expedite Cancer Detection and Treatment

By | In The Press | No Comments

Liquid Biotech USA Inc. and MolecularMatch Partner to Expedite Cancer Detection and Treatment: Partnership combines cutting-edge, liquid biopsy cancer screening with treatment data and real-time treatment matching

HOUSTON, TX (April 28, 2016) — Liquid Biotech USA Inc., a company whose liquid biopsy technology identifies circulating tumor cells in patients’ bloodstreams, and MolecularMatch, a platform that matches genomic cancer data to viable treatment options, have joined together to form a strategic partnership aimed at expediting cancer detection and treatment.

As a part of the partnership, Liquid Biotech USA will begin an exploratory phase—utilizing MolecularMatch data integrations and its treatment database to help build its technology processes. Read More

Announcing Completion of Proof-of-Concept (POC) Clinical Study that Triggers a $1M Milestone Payment from Oncolys Biopharma, Inc.

By | In The Press | No Comments

Liquid Biotech USA, Inc. Announces Completion of Proof-of-Concept (POC) Clinical Study that Triggers a $1M Milestone Payment from Oncolys Biopharma, Inc.

April 5, 2016, Philadelphia, PA

Liquid Biotech USA, Inc. (LB) today announced that a combination of pre-clinical and clinical data from a recently completed study supports its diagnostic bladder and lung cancer test in a clinical setting. The completion of the clinical POC meets the milestone requirements’ as set out by our partner, Oncolys Biopharma, Inc. (TYO:4588; OBP), and triggers a $1M payment. The diagnostic test is based on a proprietary platform technology developed by OBP and The University of Pennsylvania and exclusively licensed for North America by LB. The technology can identify, enumerate and isolate individual circulating tumor cells (CTCs) found in the blood of cancer patients – a liquid biopsy. CTCs are identified due to their expression of telomerase; an enzyme that is expressed in many forms of cancer but shows little to no activity in non-malignant cells.

Read More

Liquid Biotech USA, Inc. is pleased to announce being selected as a Finalist in the 2016 Enterprise Awards Life Sciences Startup Category

By | In The Press | No Comments

Liquid Biotech USA, Inc. is pleased to announce being selected as a Finalist in the 2016 Enterprise Awards Life Sciences Startup Category

February 16, 2016, Philadelphia, PA

The Company is honored to announce that it has been selected as a finalist for the 2016 Enterprise Awards for Life Sciences Startup. The Enterprise Awards, presented by PACT and in partnership with KPMG, recognizes and honors leadership and outstanding achievement in the technology, healthcare and life sciences industries throughout the Philadelphia area. The criteria for the award for a Life Sciences Startup Company includes being in operation for three years or less, a product or innovative technology with high potential for rapid market growth, as well as a management team with a proven record of accomplishment.

Read More

Announcement of TelomeScan® License Agreement and Business Alliance in North America

By | In The Press | No Comments

The Board of Onoclys BioPharma (“Oncolys”) is pleased to announce that it has resolved, at its board meeting on the 24 November 2015, to enter into a license agreement and business alliance with Liquid Biotech USA, Inc. (“Liquid Biotech”) for cancer detection modality OBP-401 (TelomeScan®), in order to further accelerate its business development activities in North America.

Read More